ISRACANN Biosciences: Invest in Israel’s First Cannabis Pure-Play Public Offering
Ryan Allway
April 4th, 2019
Exclusive, News, Top Story
North America may be capturing most of the headlines when it comes to the cannabis industry, but other global cannabis frontier markets could offer greater growth potential. Israel is already well-known as the cannabis research capital of the world. Similarly, it also has a nascent domestic cannabis industry with one of the highest ratios of cannabis consumers in the world and is well-positioned to become a leading exporter to Europe.
ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)] will be Israel’s first pure-play cannabis company to list on a Canadian exchange, with three licensed farms totaling 580,000 sq. ft. With plans to initially target an undersupplied domestic market before exporting into Europe, investors may want to keep an eye on the stock as it gears up to go public in Canada under the ticker symbol IPOT later this year.
Click Here: Learn how to invest in ISRACANN Biosciences as an Accredited Investor.
ISRACANN’s Unique Advantage
President and CEO Darryl Jones has over 15 years of experience in the capital markets where he raised risk capital for growth companies in the medical cannabis and natural resource sectors. In 2014, he took True Leaf Medicine public at a $10 million valuation and exited in 2016 at a $150 million market capitalization. He’s joined by an experienced team of cannabis and finance veterans with an established track record of success.
The company’s business model centers on four pillars:
- Cultivation: Israel’s climate provides the ideal conditions for low-cost production of high-quality cannabis. The company partnered with Yamko, a leading global construction firm, to ensure industry-leading facilities are constructed.
- Distribution: Israel has a massive domestic market with over 10,000 patients on a wait
list and the potential for 50,000 patients by 2019. In addition, its proximity to Europe provides an efficient path to export growth.
- Branding: Israel’s well-known leadership position in cannabis research could set its products apart on the global market in the same way that Swiss watches have become the most popular brand of watch around the world.
- Research: Partnership with leading Israeli research institutions and Universities to leverage their expertise and bring novel products to market.
Currently, the company has agreements with three farms in Israel with cultivation licenses totaling 580,000 sq. ft. These operations have a fully-funded capacity of 232,900 sq. ft. with the ability to produce 23,500 kilograms of cannabis per year, and they’re scalable to 580,000 sq. ft. producing 50,000 kilograms of cannabis per year. Management believes that production costs could be as low as 40 cents per gram given the ideal climate and technology.
Click Here: Learn how to invest in ISRACANN Biosciences as an Accredited Investor.
Israel’s Cannabis Industry
Israel has a well-earned reputation for being the world’s cannabis research capital. In 1964, Dr. Raphael Mechoulam isolated tetrahydrocannabinol (THC and CBO) at the Weizmann Institute of Science in Rehovot, Israel. Nearly three decades later, Israeli researchers discovered the endogenous cannabinoid anandamide. The country has been a pioneer in the research and development of cannabinoid technologies and therapeutics ever since.
The country’s government is also very supportive of the cannabis industry—unlike the United States. In 2007, Israel became the first country to allow both medical research and cannabis cultivation while also decriminalizing the recreational use of cannabis. There are already more than 10,000 patients in Israel that are currently on a waiting list for medical cannabis and the country has one of the highest ratios of cannabis consumers in the world.
Israel’s proximity to Europe also makes it an attractive springboard to much larger markets. The government approved cannabis exports earlier this year and analysts believe that regulations could be in place later this year. The European continent as a whole is home to 740 million people, which is double the population of Canada and the United States, the two largest cannabis markets today.
Looking Ahead
ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)] plans to become fully operational with harvests expected by late in the fourth quarter of this year. Given the strong valuations across North American cannabis companies, investors may want to keep a close eye on the stock ahead of its listing on a Canadian Stock Exchange later this year. The unique exposure to Israel’s market and the potential to expand into Europe could drive significant long-term value.
Click Here: Learn how to invest in ISRACANN Biosciences as an Accredited Investor.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Christina Lake Cannabis Corp. is a licensed producer of cannabis under the Cannabis Act.
Chemesis International is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
